Sprott Inc’s Inhibikase Therapeutics IKT Stock Holding History

Sprott Inc’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,667	Closed	-$5K	–	136
2022 Q4	$5K	Buy	+1,667	New	+$6.61K	﹤0.01%	140

Other funds holding IKT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sprott Inc's IKT Position: Q1 2023 in Review

Sprott Inc sold out of Inhibikase Therapeutics (IKT) in Q1 2023, closing a stake of 1,667 shares — an estimated $5K sold.

Sprott Inc first reported a position in IKT in Q4 2022 and held it in 1 quarter. The position peaked at $5K in Q4 2022. 17 funds tracked by Wall St. Rank hold IKT as of Q1 2023.

Sprott Inc reported no remaining Inhibikase Therapeutics position as of Q1 2023 after selling out during the quarter.
Sprott Inc sold 1,667 Inhibikase Therapeutics shares in Q1 2023, an estimated $5K.
Sprott Inc first reported a position in Inhibikase Therapeutics in Q4 2022 and held it in 1 quarter.
Sprott Inc's Inhibikase Therapeutics position peaked at $5K in Q4 2022.
17 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2023.

Based on Sprott Inc's 13F filing for Q1 2023, filed 15 May 2023.